study on polycystic ovarian syndrome

A randomized control trial comparing unani formulaation and metformin in patients with poly cystic ovarian syndrome

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/11/037911

Enrollment

Registered

2021-11-10

Start date

Unknown

Completion date

Unknown

Last updated

2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E282- Polycystic ovarian syndrome

Interventions

Intervention1: Unani Formulation: for 3 consecutive cycles Control Intervention1: Metformin: 1000mg for 3 consecutive cycles

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients aged 18-35 2. Oligomenorrhoea or amenorrhoea 3. Clinical evidence of hyperandrogenism ( Hirsuitism / Acne) 4. USG findings of PCO

Exclusion criteria

Exclusion criteria: 1. Patients with Insulin sensitizing treatment within 3 months16 2. Patients with Hormonal treatment 3. Patients with H/o DM, Hypertension 4. Pregnant and lactating women

Design outcomes

Primary

Measure	Time frame
Menstrual regularityTimepoint: 3 cycles	—

Secondary

Measure	Time frame
USG Changes for ovarian volume, changes in FG score & Acanthosis Nigricans scale score.Timepoint: 3 cycles	—

Countries

India

Contacts

Public ContactKouser Fathima Firdose

National Institute of Unani Medicine

kouser2fathima@gmail.com9141762284

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026